microRNA‑3941 targets IGF2 to control LPS‑induced acute pneumonia in A549 cells

Fei,Shinuan; Cao,Lichun; Pan,Liangzhi

doi:10.3892/mmr.2017.8369

microRNA‑3941 targets IGF2 to control LPS‑induced acute pneumonia in A549 cells

Authors:
- Shinuan Fei
- Lichun Cao
- Liangzhi Pan
View Affiliations

Affiliations: Department of Pediatrics, Edong Healthcare Group, Huangshi Maternity and Children's Health Hospital, Huangshi, Hubei 435000, P.R. China, Department of Pediatrics, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, Hubei 435000, P.R. China, Department of Medical Records, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, Hubei 435000, P.R. China
Published online on: December 29, 2017 https://doi.org/10.3892/mmr.2017.8369
Pages: 4019-4026

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the potential roles and regulatory mechanism of microRNA (miR)-3941 in lipopolysaccharides (LPS)‑induced acute pneumonia. The expression of miR‑3941 in child patients with acute pneumonia was detected and A549 cells were treated with LPS to establish the cellular model of acute pneumonia. The effects of miR‑3941 in LPS‑induced cell injury were investigated by assessing cell viability, apoptosis and inflammation. In addition, the regulatory relationship between miR‑3941 and insulin‑like growth factor 2 (IGF2) was explored, as well as the association between miR‑3941 and the phosphatidylinositol‑4,5‑bisphosphate 3‑kinase/protein kinase B (PI3K/AKT) pathway. miR‑3941 was significantly down‑regulated in patients with acute pneumonia (P<0.01). In the cell model of acute pneumonia, LPS treatment significantly induced cell injury via inhibiting cell viability (P<0.05 or P<0.01), inducing cell apoptosis (P<0.01) and enhancing the production of cytokines [interleukin (IL)‑6, IL‑8 and tumor necrosis factor‑α; P<0.01 or P<0.001]. LPS treatment also resulted in a significantly decreased expression of miR‑3941 in A549 cells (P<0.01) and the overexpression of miR‑3941 significantly alleviated LPS‑induced cell injury (P<0.05). In addition, IGF2 was confirmed as a direct target gene of miR‑3941. Knockdown of IGF2 significantly alleviated LPS‑induced cell injury (P<0.05, P<0.01 or P<0.001), which was significantly reversed by suppression of miR‑3941 (P<0.05, P<0.01 or P<0.001). Furthermore, inhibition of miR‑3941 was demonstrated to activate the PI3K/AKT pathway, which was inhibited following knockdown of IGF2. The present study indicates that miR‑3941 is downregulated in child patients with acute pneumonia and that downregulation of miR‑3941 may promote LPS‑induced cell injury in A549 cells via targeting IGF2 to regulate the activation of the PI3K/AKT pathway. Therefore, miR‑3941 may be a potential therapeutic target for the treatment of acute pneumonia in child patients.

View Figures

View References

1	Li W, An X, Fu M and Li C: Emergency treatment and nursing of children with severe pneumonia complicated by heart failure and respiratory failure: 10 case reports. Exp Ther Med. 12:2145–2149. 2016. View Article : Google Scholar : PubMed/NCBI
2	Chen CH, Wen HJ, Chen PC, Lin SJ, Chiang TL, Hsieh IC and Guo YL: Prenatal and postnatal risk factors for infantile pneumonia in a representative birth cohort. Epidemiol Infect. 140:1277–1285. 2011. View Article : Google Scholar : PubMed/NCBI
3	Lin LJ, Wang YC and Liu XM: Clinical and immunological features of common variable immunodeficiency in China. Chin Med J (Engl). 128:310–315. 2015. View Article : Google Scholar : PubMed/NCBI
4	Pancer KW: Problem of immunoglobulin M co-detection in serological response to bacterial and viral respiratory pathogens among children suspected of legionellosis. Cent Eur J Immunol. 40:174–179. 2015. View Article : Google Scholar : PubMed/NCBI
5	O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS and Cherian T; Hib and Pneumococcal Global Burden of Disease Study Team, : Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates. Lancet. 374:893–902. 2009. View Article : Google Scholar : PubMed/NCBI
6	Hammond SM: An overview of microRNAs. Adv Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
7	Chapman CG and Pekow J: The emerging role of miRNAs in inflammatory bowel disease: A review. Therap Adv Gastroenterol. 8:4–22. 2015. View Article : Google Scholar : PubMed/NCBI
8	Meijer HA, Kong YW, Lu WT, Wilczynska A, Spriggs RV, Robinson SW, Godfrey JD, Willis AE and Bushell M: Translational repression and eIF4A2 activity are critical for microRNA-mediated gene regulation. Science. 340:82–85. 2013. View Article : Google Scholar : PubMed/NCBI
9	Schickel R, Boyerinas B, Park Sm and Peter M: MicroRNAs: Key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 27:5959–5974. 2008. View Article : Google Scholar : PubMed/NCBI
10	Su Z, Yang Z, Xu Y, Chen Y and Yu Q: MicroRNAs in apoptosis, autophagy and necroptosis. Oncotarget. 6:8474–8490. 2015. View Article : Google Scholar : PubMed/NCBI
11	Acunzo M, Romano G, Wernicke D and Croce CM: MicroRNA and cancer-a brief overview. Adv Biol Regul. 57:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
12	Cao DD, Li L and Chan WY: MicroRNAs: Key regulators in the central nervous system and their implication in neurological diseases. Int J Mol Sci. 17:8422016. View Article : Google Scholar :
13	Oglesby IK, Mcelvaney NG and Greene CM: MicroRNAs in inflammatory lung disease-master regulators or target practice? Respir Res. 11:1482010. View Article : Google Scholar : PubMed/NCBI
14	Plank M, Maltby S, Mattes J and Foster PS: Targeting translational control as a novel way to treat inflammatory disease: The emerging role of microRNAs. Clin Exp Allergy. 43:981–999. 2013. View Article : Google Scholar : PubMed/NCBI
15	Sato T, Shiba-Ishii A, Kim Y, Dai T, Husni RE, Hong J, Kano J, Sakashita S, Iijima T and Noguchi M: miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma. Cancer Sci. 108:536–542. 2017. View Article : Google Scholar : PubMed/NCBI
16	Berillo O, Régnier M and Ivashchenko A: Binding of intronic miRNAs to the mRNAs of host genes encoding intronic miRNAs and proteins that participate in tumourigenesis. Comput Biol Med. 43:1374–1381. 2013. View Article : Google Scholar : PubMed/NCBI
17	Wang HM, Lu JH, Chen WY and Gu AQ: Upregulated lncRNA-UCA1 contributes to progression of lung cancer and is closely related to clinical diagnosis as a predictive biomarker in plasma. Int J Clin Exp Med. 8:11824–11830. 2015.PubMed/NCBI
18	Li W, Qiu X, Jiang H, Han Y, Wei D and Liu J: Downregulation of miR-181a protects mice from LPS-induced acute lung injury by targeting Bcl-2. Biomed Pharmacother. 84:1375–1382. 2016. View Article : Google Scholar : PubMed/NCBI
19	Ke XF, Fang J, Wu XN and Yu CH: MicroRNA-203 accelerates apoptosis in LPS-stimulated alveolar epithelial cells by targeting PIK3CA. Biochem Biophys Res Commun. 450:1297–1303. 2014. View Article : Google Scholar : PubMed/NCBI
20	Xu Z, Dong D, Chen X, Huang H and Wen S: MicroRNA-381 negatively regulates TLR4 signaling in A549 cells in response to LPS stimulation. Biomed Res Int. 2015:8494752015. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Dai R and Ahmed SA: MicroRNA, a new paradigm for understanding immunoregulation, inflammation and autoimmune diseases. Transl Res. 157:163–179. 2011. View Article : Google Scholar : PubMed/NCBI
23	Yamasaki T, Kim EJ, Cerutti H and Ohama T: Argonaute3 is a key player in miRNA-mediated target cleavage and translational repression in Chlamydomonas. Plant J. 85:258–268. 2016. View Article : Google Scholar : PubMed/NCBI
24	Chao W and D'Amore PA: IGF2: Epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev. 19:111–120. 2008. View Article : Google Scholar : PubMed/NCBI
25	Corkins MR, Gohil AD and Fitzgerald JF: The insulin-like growth factor axis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 36:228–234. 2003. View Article : Google Scholar : PubMed/NCBI
26	Matouk IJ, Halle D, Gilon M and Hochberg A: The non-coding RNAs of the H19-IGF2 imprinted loci: A focus on biological roles and therapeutic potential in lung cancer. J Transl Med. 13:1132015. View Article : Google Scholar : PubMed/NCBI
27	Jang HJ, Boo HJ, Lee HJ, Min HY and Lee HY: Chronic stress facilitates lung tumorigenesis by promoting exocytosis of IGF2 in lung epithelial cells. Cancer Res. 76:6607–6619. 2016. View Article : Google Scholar : PubMed/NCBI
28	Li P: Clinical significance of changes of serum IGF-II, IL-2, IL-10 and TNF-α levels after treatment in children with bronchopneumonia. J Radioimmunol. 19:288–289. 2006.
29	Qiu-qing D: Measurement of changes of serum IGF-II, hs-CRP and M-CSF levels after treatment in pediatric patients with bron-chopneumonia. J Huaihai Med. 6:112011.
30	McLaughlin KJ, Kochanowski H, Solter D, Schwarzkopf G, Szabó PE and Mann JR: Roles of the imprinted gene Igf2 and paternal duplication of distal chromosome 7 in the perinatal abnormalities of androgenetic mouse chimeras. Development. 124:4897–4904. 1997.PubMed/NCBI
31	Yamamoto K, Ferrari JD, Cao Y, Ramirez MI, Jones MR, Quinton LJ and Mizgerd JP: Type I alveolar epithelial cells mount innate immune responses during pneumococcal pneumonia. J Immunol. 189:2450–2459. 2011. View Article : Google Scholar
32	Weichhart T and Säemann MD: The PI3K/Akt/mTOR pathway in innate immune cells: Emerging therapeutic applications. Ann Rheum Dis. 67 Suppl 3:iii70–iii74. 2008. View Article : Google Scholar : PubMed/NCBI
33	Xie S, Chen M, Yan B, He X, Chen X and Li D: Identification of a role for the PI3K/AKT/mTOR signaling pathway in innate immune cells. PLoS One. 9:e944962014. View Article : Google Scholar : PubMed/NCBI
34	Chen XF, Zhang HJ, Wang HB, Zhu J, Zhou WY, Zhang H, Zhao MC, Su JM, Gao W, Zhang L, et al: Transforming growth factor-β1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways. Mol Biol Rep. 39:3549–3556. 2012. View Article : Google Scholar : PubMed/NCBI
35	Chetty C, Lakka SS, Bhoopathi P and Rao JS: MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer. 127:1081–1095. 2010. View Article : Google Scholar : PubMed/NCBI